Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2007053194) MODULATION OF CELL BARRIER DYSFUNCTION
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2007/053194 International Application No.: PCT/US2006/021604
Publication Date: 10.05.2007 International Filing Date: 05.06.2006
IPC:
A61K 31/451 (2006.01) ,A61K 31/485 (2006.01) ,A61K 39/395 (2006.01) ,A61K 45/06 (2006.01) ,A61P 31/04 (2006.01) ,A61P 35/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
445
Non-condensed piperidines, e.g. piperocaine
451
having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
47
Quinolines; Isoquinolines
485
Morphinan derivatives, e.g. morphine, codeine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
04
Antibacterial agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
THE UNIVERSITY OF CHICAGO [US/US]; 5801 South Ellis Avenue Chicago, IL 60637, US (AllExceptUS)
ALVERDY, John, C. [US/US]; US (UsOnly)
MOSS, Jonathan [US/US]; US (UsOnly)
LINGEN, Mark, W. [US/US]; US (UsOnly)
SINGLETON, Patrick, A. [US/US]; US (UsOnly)
GARCIA, Joe, G.n. [US/US]; US (UsOnly)
Inventors:
ALVERDY, John, C.; US
MOSS, Jonathan; US
LINGEN, Mark, W.; US
SINGLETON, Patrick, A.; US
GARCIA, Joe, G.n.; US
Agent:
WELCH, Teresa, J.; Michael Best & Friedrich LLP One South Pinckney Street P.O. Box 1806 Madison, WI53701-1806, US
Priority Data:
60/687,56803.06.2005US
60/731,00928.10.2005US
60/760,85120.01.2006US
PCT/US2006/0789207.03.2006US
Title (EN) MODULATION OF CELL BARRIER DYSFUNCTION
(FR) MODULATION DES DYSFONCTIONNEMENTS DE LA BARRIERE CELLULAIRE
Abstract:
(EN) The invention provides prophylactic and therapeutic methods for administering a μ-opioid receptor antagonist to treat cell barrier diseases and disorders, such as endothelial and epithelial cell barrier diseases and disorders. The diseases or disorders may amenable to the methods include inflammation, such as acute lung injury, atherosclerosis, gut-derived sepsis, a burn injury, neonatal necrotizing enterocolitis, severe neutropenia, toxic colitis, inflammatory bowel disease, enteropathy, transplant rejection, pouchitis, pig belly (pig-bel), Pseudomonas-mediated ophthalmologic infection, Pseudomonas-mediated otologic infection and Pseudomonas-mediated cutaneous infection. More generally, epithelial cell barrier disorders are contemplated as amenable to the prophylactic and therapeutic methods.. The diseases and disorders may be induced by microbial pathogens, including bacterial pathogens such as Pseudomon&agr;s aeruginosa. The invention further provides prophylactic and therapeutic methods for inhibiting the expression of bacterial PA-I lectin/adhesin and for inhibiting bacterial MvfR activity levels. Also provided is a method of using a μ-opioid receptor antagonist in the manufacture of a medicament for use in the methods described herein.
(FR) L'invention concerne des procédés prophylactiques et thérapeutiques d'administration d'un antagoniste des récepteurs des µ-opioïdes pour traiter les maladies et les affections de la barrière cellulaire, par exemple les maladies et les affections de la barrière des cellules endothéliales et des cellules épithéliales. Les maladies ou affections concernés par les procédés sont l'inflammation, par exemple les lésions aiguës des poumons, l'athérosclérose, la septicémie d'origine viscérale, les lésions par brûlure, l'entérocolite nécrotique néonatale, la neutropénie grave, la colite toxique, les maladies inflammatoires des viscères, l'entéropathie, le rejet des transplants, la pouchite, l'entérite nécrotique, les infections ophtalmiques médiées par Pseudomonas, les infections otologiques médiées par Pseudomonas et les infections cutanées médiées par Pseudomonas. De manière plus générale, les procédés prophylactiques et thérapeutiques concernés peuvent être envisagés pour traiter les affections de la barrière des cellules épithéliales. Les maladies et les affections peuvent être induits par des pathogènes microbiens, notamment des pathogènes bactériens tels que Pseudomonas aeruginosa. L'invention concerne en outre des procédés prophylactiques et thérapeutiques qui inhibent l'expression de la lectine/adhésine PA-I bactérienne et d'inhibition des niveaux d'activité des MvfR bactériens. L'invention concerne également un procédé utilisant un antagoniste des récepteurs des µ-opioïdes pour la fabrication d'un médicament destiné à être utilisé dans les procédés qu'elle décrit.
front page image
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP1901742JP2008542395US20080194611CA2609985AU2006309292